ENDPOINTS

CureVac CEO on the $1.25B BioNTech deal

After 25 years of trying to lead biopharma's mRNA revolution across infectious diseases and cancer, German biotech CureVac made the surprise announcement Thursday morning that it would exit to its rival and ...

Jun 12, 2025 - 19:50
 0
CureVac CEO on the $1.25B BioNTech deal
After 25 years of trying to lead biopharma's mRNA revolution across infectious diseases and cancer, German biotech CureVac made the surprise announcement Thursday morning that it would exit to its rival and ...
Read More

Tags:

Previous Article

Federal R&D funding boosts productivity for the whole economy. Making big cuts t...

Next Article

Texas Approves Use Of Fracking Wastewater To Irrigate Crops

Related Posts

AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset

AGC Bio secures lentiviral contract; Thermo Fisher to m...

May 15, 2025  0

Pharma companies consider first sale rule to ease tariff impact

Pharma companies consider first sale rule to ease tarif...

May 22, 2025  0

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

SK, Carlyle bolster bluebird bio bid; Therini Bio raise...

May 14, 2025  0